SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

NPPA slashes prices of 8 popular drugs by up to 85

18 Oct 2010 Evaluate

The country’s drug price regulator has reduced prices of eight medicines sold by leading pharma companies such as Cipla, Sun Pharma and Unichem by up to 85%, in one of the sharpest price cuts over the past few years. The prices of seven of these eight brands have been fixed by the drug price regulator for the first time. NPPA prescribes a price ceiling for drugs containing any of the 74 chemicals that are under price control to contain the cost of medication for consumers. 

The maximum price for Cipla’s popular combination antibiotic, Ciplox TZ, has been cut by 74% from Rs 100.73 to Rs 25.7 (excluding taxes) for a 10-tablet strip. The price of Rexcin Pharmaceuticals’ popular burn ointment, Silverex AV cream, has been slashed by around 85% to Rs 25 for a 20-gm tube. The regulator has also slashed the price of Cosmo Life Sciences vitamin capsules Lycobal Forte by 88.7% to Rs 8.90 (excluding taxes) for 10 capsules. The other medicines whose prices have been cut include JB Remedies’ Nor-Tz tablets and Okassa Pharma’s Burn Heal cream. 

Most of the medicines whose prices have been cut are combination drugs i.e. drugs that have more than one molecule. As per Indian laws, a combination drug that contains an ingredient that is under price control has to automatically conform to the price ceiling mandated by the drug price regulator. The drugmakers have to revise their prices within 15 days of the notification, failing which they could be penalised for overcharging consumers. 

crackcrack

Cipla Share Price

1294.75 -11.10 (-0.85%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×